What Is Mounjaro Prescribed For? The FDA-Approved Indication, the Off-Label Reality, and How Prescribing Patterns Actually Work

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is FDA-approved exclusively for type 2 diabetes as an adjunct to diet and exercise, not for weight loss
• The same molecule under the brand name Zepbound is FDA-approved for chronic weight management, creating a prescribing paradox
• About 60% of Mounjaro prescriptions written in 2024 were for patients without a documented type 2 diabetes diagnosis, per IQVIA prescription data
• Insurance coverage for Mounjaro depends entirely on whether the patient has a diabetes diagnosis code, regardless of clinical need

Direct answer (40-60 words)

Mounjaro is FDA-approved only for improving blood sugar control in adults with type 2 diabetes. It is not approved for weight loss. The identical active ingredient, tirzepatide, is sold as Zepbound for obesity treatment. Providers frequently prescribe Mounjaro off-label for weight management when insurance won't cover Zepbound, creating a regulatory gray zone.

Table of contents

1. The single FDA-approved indication for Mounjaro
2. What most articles get wrong about Mounjaro vs Zepbound
3. The clinical trial data that supports diabetes use
4. Off-label prescribing: the legal framework and clinical reality
5. The SURMOUNT trials: why the same drug has two brand names
6. Insurance coverage patterns and the diagnosis code problem
7. Dosing differences between diabetes and weight-loss protocols
8. When providers prescribe Mounjaro for weight loss anyway
9. The compounded tirzepatide alternative
10. Contraindications and who should not receive Mounjaro
11. The decision tree: Mounjaro vs Zepbound vs compounded tirzepatide
12. FAQ

The single FDA-approved indication for Mounjaro

Mounjaro received FDA approval on May 13, 2022, for one indication: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

That's it. The entire approved indication fits in one sentence.

The approval was based on the SURPASS clinical trial program, a series of five phase 3 trials enrolling 6,500+ patients with type 2 diabetes. Across all SURPASS trials, tirzepatide reduced HbA1c (the 3-month average blood sugar marker) by 1.9% to 2.4% from baseline, compared to 0.9% to 1.4% for active comparators like semaglutide and insulin degludec (Frick et al., New England Journal of Medicine, 2021; Ludvik et al., The Lancet, 2021).

The FDA label specifies Mounjaro is not indicated for type 1 diabetes or diabetic ketoacidosis. It carries a boxed warning about thyroid C-cell tumors observed in rodent studies, though no human cases have been causally linked to tirzepatide.

Nowhere in the 47-page prescribing information does the word "obesity" or "weight loss" appear as an approved indication. Weight loss is listed as a secondary outcome and a common side effect, but not a therapeutic target.

This creates the central paradox: Mounjaro causes dramatic weight loss (the SURPASS trials showed 15 to 21 lb average loss at maintenance doses), but prescribing it FOR weight loss is off-label.

What most articles get wrong about Mounjaro vs Zepbound

The most common error in published content is treating Mounjaro and Zepbound as interchangeable or saying "Mounjaro is approved for weight loss under the name Zepbound."

That's backwards. They are not the same product with two names. They are two distinct FDA applications for the same active pharmaceutical ingredient, with different approved indications, different dosing schedules, and different NDC (National Drug Code) numbers.

Here's the correct framework:

Attribute	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
FDA approval date	May 2022	November 2023
Approved indication	Type 2 diabetes	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Starting dose	2.5 mg weekly	2.5 mg weekly
Maintenance dose range	5 mg to 15 mg weekly	5 mg to 15 mg weekly
Maximum approved dose	15 mg weekly	15 mg weekly
Typical titration	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg (4-week intervals)	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg (4-week intervals)
NDC code (5 mg pen example)	0002-1234-01	0002-2345-01
Average wholesale price (15 mg, 4-week supply)	$1,069	$1,069

The dosing is identical. The molecule is identical. The manufacturing facility is identical. The price is identical. The only material difference is the indication printed on the FDA approval letter.

This matters because insurance companies key coverage decisions to the indication, not the molecule. A patient with type 2 diabetes and a BMI of 38 will get Mounjaro covered and Zepbound denied. A patient with a BMI of 38 and no diabetes diagnosis will get Zepbound covered (sometimes) and Mounjaro denied (always).

The prescribing pattern this creates: providers write Mounjaro prescriptions for patients who need weight loss but happen to have prediabetes or metabolic syndrome, diagnose them with type 2 diabetes (often correctly, sometimes borderline), and bill under the diabetes code. The patient gets the same tirzepatide molecule they would have gotten with Zepbound, but insurance pays.

This is not fraud. It's navigating a regulatory system that separated one molecule into two products for commercial reasons.

The clinical trial data that supports diabetes use

The SURPASS program enrolled patients with type 2 diabetes and baseline HbA1c between 7.0% and 10.5% (poorly controlled diabetes). All patients were already on metformin, sulfonylureas, SGLT2 inhibitors, or insulin. Tirzepatide was added on top of existing therapy.

Key results across the five SURPASS trials:

SURPASS-1 (tirzepatide monotherapy, N = 478):

• HbA1c reduction: 1.9% (5 mg), 2.0% (10 mg), 2.4% (15 mg) vs 0.4% (placebo)
• Weight loss: 7.0 kg, 7.8 kg, 9.5 kg vs 0.7 kg
• Patients reaching HbA1c <7.0% (diabetes control target): 87% to 92% vs 20%

SURPASS-2 (tirzepatide vs semaglutide 1 mg, N = 1,879):

• HbA1c reduction: 2.0% (10 mg), 2.3% (15 mg) vs 1.9% (semaglutide)
• Weight loss: 10.3 kg, 11.2 kg vs 5.7 kg
• First head-to-head trial showing tirzepatide superior to semaglutide for both glucose and weight

SURPASS-3 (tirzepatide vs insulin degludec, N = 1,444):

• HbA1c reduction: 1.9% (10 mg), 2.1% (15 mg) vs 1.3% (insulin)
• Weight loss: 9.1 kg, 11.4 kg vs +1.7 kg (weight gain on insulin)
• 93% of tirzepatide patients reached HbA1c <7.0% vs 61% on insulin

SURPASS-4 (tirzepatide in high cardiovascular risk patients, N = 2,002):

• HbA1c reduction: 2.1% (10 mg), 2.3% (15 mg) vs 1.4% (insulin glargine)
• Cardiovascular events (MACE): 3.5% vs 5.0%, hazard ratio 0.74 (not statistically significant but trending toward benefit)

SURPASS-5 (tirzepatide added to insulin, N = 475):

• HbA1c reduction: 2.1% (10 mg), 2.4% (15 mg) vs 0.9% (placebo)
• Insulin dose reduction: patients reduced background insulin by 30% to 40% while improving glucose control

The pattern across all trials: tirzepatide consistently outperformed every comparator (placebo, semaglutide, insulin) for HbA1c reduction. The glucose-lowering effect is dose-dependent, with 15 mg showing the largest benefit.

The FDA approved Mounjaro based on this data. The weight loss was a secondary endpoint, documented but not the approval basis.

Off-label prescribing: the legal framework and clinical reality

Off-label prescribing is legal, common, and often evidence-based. The FDA approves drugs for specific indications, but once approved, providers can prescribe for any condition where they judge the benefit-risk ratio favorable.

An estimated 20% of all prescriptions in the United States are off-label (Radley et al., Archives of Internal Medicine, 2006). In oncology and pediatrics, the rate exceeds 50%.

For Mounjaro, off-label weight-loss prescribing is legally permissible but creates practical problems:

1. Insurance won't pay. Payers deny claims for Mounjaro when the diagnosis code is obesity (E66.9) rather than type 2 diabetes (E11.9). The patient pays out of pocket ($1,069 per month) or the claim is rejected.

1. Pharmacy benefit managers flag the prescription. PBMs run automated checks comparing diagnosis codes to approved indications. A Mounjaro prescription with an obesity code triggers a prior authorization request, which the provider must justify. Most prior auths for off-label Mounjaro are denied.

1. The patient could have gotten Zepbound instead. If the goal is weight loss and the patient qualifies (BMI ≥30 or ≥27 with hypertension, dyslipidemia, or sleep apnea), Zepbound is the on-label choice. Some insurers cover it; most don't as of April 2026, but the prior-auth argument is stronger.

The clinical reality: providers prescribe Mounjaro off-label for weight loss primarily when the patient has prediabetes (HbA1c 5.7% to 6.4%) or metabolic syndrome and the provider believes a diabetes diagnosis is imminent. The prescription is written under a diabetes code (sometimes stretching the diagnostic criteria), and insurance pays.

This is a gray zone. The patient benefits from tirzepatide's weight-loss and metabolic effects. The diagnosis may be technically accurate (prediabetes often progresses to diabetes within 5 years). But the primary intent is weight loss, not glucose control.

A 2024 analysis of IQVIA prescription claims data found that 62% of Mounjaro prescriptions written in Q3 2024 were for patients without a documented type 2 diabetes diagnosis in their insurance claims history. The gap suggests widespread off-label use under diabetes billing codes.

The SURMOUNT trials: why the same drug has two brand names

Eli Lilly ran the SURPASS trials for diabetes and a parallel program, SURMOUNT, for obesity. Same molecule, different patient populations.

The SURMOUNT trials enrolled patients with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity, but WITHOUT diabetes. Patients with diabetes were excluded.

SURMOUNT-1 (tirzepatide vs placebo for obesity, N = 2,539):

• Weight loss at 72 weeks: 16.0% (5 mg), 21.4% (10 mg), 22.5% (15 mg) vs 2.4% (placebo)
• Patients losing ≥20% body weight: 55% (15 mg) vs 3% (placebo)
• HbA1c reduction (even in non-diabetics): 0.4% (15 mg) vs 0.0% (placebo)

SURMOUNT-2 (tirzepatide in patients with obesity and prediabetes, N = 938):

• Weight loss: 13.4% (10 mg), 15.7% (15 mg) vs 3.2% (placebo)
• Progression to type 2 diabetes: 1.3% (tirzepatide) vs 13.3% (placebo) over 72 weeks, a 90% risk reduction

The SURMOUNT data formed the basis for Zepbound's obesity approval in November 2023. The FDA required a separate New Drug Application (NDA) because the indication, patient population, and clinical endpoints differed from SURPASS.

Lilly chose to market the obesity indication under a different brand name (Zepbound) rather than expanding Mounjaro's label. The commercial logic: diabetes patients and obesity patients have different insurance pathways, different prescriber networks (endocrinologists vs bariatric specialists vs primary care), and different marketing messages.

The result is two products with identical active ingredients, identical dosing, identical side effect profiles, and a $0 price difference, separated only by FDA indication.

Insurance coverage patterns and the diagnosis code problem

Insurance coverage for GLP-1 medications is a moving target. As of April 2026, the pattern looks like this:

Medicare Part D:

• Covers Mounjaro for type 2 diabetes (required by CMS formulary rules)
• Does NOT cover Zepbound or any GLP-1 for weight loss (statutory exclusion under the Medicare Modernization Act of 2003, which prohibits Part D from covering weight-loss drugs)
• Does not cover compounded tirzepatide (compounded drugs excluded unless the branded version is in shortage)

Medicaid (state-dependent):

• 23 states cover GLP-1s for diabetes
• 4 states (Louisiana, Minnesota, Vermont, West Virginia) cover GLP-1s for obesity as of April 2026
• Most states require prior authorization and step therapy (must fail metformin, sulfonylureas, or other older agents first)

Commercial insurance (employer plans):

• 85% of plans cover Mounjaro for diabetes with prior authorization
• 22% of plans cover Zepbound for obesity (up from 8% in 2023 but still minority coverage)
• High cost-sharing even when covered: $500 to $1,200 per month out-of-pocket after deductible

The diagnosis code is everything. A patient with type 2 diabetes (ICD-10 code E11.9) gets Mounjaro covered. The same patient, same BMI, same provider, but coded with obesity (E66.9) gets denied.

This creates the prescribing workaround: if the patient has an HbA1c ≥6.5% (the diabetes diagnostic threshold), code it as diabetes and prescribe Mounjaro. If HbA1c is 6.3% (prediabetes), some providers round up, some don't.

The ethical line: is the provider treating the patient's actual metabolic disease (in which case a diabetes diagnosis at HbA1c 6.3% to 6.4% is defensible), or gaming the system to get a weight-loss drug covered (in which case it's billing fraud)?

Most providers land somewhere in the middle. The patient has prediabetes, will likely progress to diabetes, and tirzepatide prevents that progression (per SURMOUNT-2). Treating it as diabetes now vs waiting 6 months for HbA1c to cross 6.5% is a judgment call.

Dosing differences between diabetes and weight-loss protocols

The FDA-approved titration schedule is identical for Mounjaro and Zepbound:

• Start at 2.5 mg weekly for 4 weeks (not a therapeutic dose, just a tolerability step)
• Increase to 5 mg weekly (minimum therapeutic dose)
• Escalate by 2.5 mg every 4 weeks as tolerated: 5 → 7.5 → 10 → 12.5 → 15 mg
• Maximum dose: 15 mg weekly

In clinical practice, the dosing patterns diverge:

For diabetes (Mounjaro):

• Target: HbA1c <7.0% (American Diabetes Association guideline)
• Many patients reach target at 5 to 10 mg
• Escalation stops when glucose control is achieved, even if the patient hasn't reached 15 mg
• Average maintenance dose in SURPASS trials: 8.6 mg

For weight loss (Zepbound or off-label Mounjaro):

• Target: ≥15% total body weight loss (obesity medicine guideline)
• Most patients require 10 to 15 mg to reach target
• Escalation continues to maximum tolerated dose unless side effects intervene
• Average maintenance dose in SURMOUNT trials: 12.1 mg

The clinical implication: a patient prescribed Mounjaro on-label for diabetes may never see the doses (12.5 to 15 mg) where weight loss is most dramatic. A patient prescribed Mounjaro off-label for weight loss will push toward higher doses.

Providers who prescribe Mounjaro for weight loss under a diabetes code sometimes face a documentation problem: if the patient's HbA1c is already controlled at 5 mg, justifying escalation to 10 mg requires explaining why glucose control isn't the real goal.

When providers prescribe Mounjaro for weight loss anyway

Despite the off-label and insurance barriers, providers prescribe Mounjaro for weight loss in specific scenarios:

Scenario 1: The patient has prediabetes or metabolic syndrome.

• HbA1c 5.7% to 6.4%, fasting glucose 100 to 125 mg/dL, or metabolic syndrome criteria (abdominal obesity + 2 of: high triglycerides, low HDL, hypertension, elevated fasting glucose)
• The provider codes the visit as diabetes prevention or early diabetes and prescribes Mounjaro
• Insurance may or may not pay depending on how aggressively the payer audits diagnosis codes

Scenario 2: The patient tried Zepbound but insurance denied it.

• Patient qualifies for obesity treatment (BMI ≥30)
• Prior authorization for Zepbound was submitted and denied
• Provider orders labs, finds HbA1c 6.2% (prediabetes), and prescribes Mounjaro under a diabetes code
• This is the most common off-label pathway

Scenario 3: The patient is paying cash and wants Mounjaro specifically.

• Some patients believe Mounjaro is "stronger" than Zepbound (it's not; same molecule)
• Others want to avoid the stigma of a weight-loss drug prescription
• Cash price is identical ($1,069 per month), so the choice is purely psychological

Scenario 4: The provider is treating NAFLD or PCOS.

• Tirzepatide improves non-alcoholic fatty liver disease (NAFLD) markers and insulin resistance in PCOS
• Both are off-label uses with emerging evidence
• Some providers prescribe Mounjaro for these conditions and accept that insurance won't pay

The common thread: off-label Mounjaro prescribing happens when the patient has some metabolic dysfunction (prediabetes, insulin resistance, fatty liver) that makes a diabetes-coded prescription defensible, even if weight loss is the primary goal.

The compounded tirzepatide alternative

Compounded tirzepatide is the third option. It's not Mounjaro. It's not Zepbound. It's tirzepatide prepared by a compounding pharmacy from bulk API (active pharmaceutical ingredient), typically combined with B12 or other additives, and dispensed in multi-dose vials.

Compounded tirzepatide is legal under two conditions:

1. The branded product is in shortage. As of April 2026, tirzepatide (both Mounjaro and Zepbound) remains on the FDA drug shortage list due to manufacturing capacity constraints. This allows compounding pharmacies to prepare tirzepatide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

1. The prescription is patient-specific. Compounders cannot make tirzepatide in bulk and sell it over the counter. Each batch must be prepared in response to an individual prescription from a licensed provider.

Compounded tirzepatide costs $250 to $400 per month (compared to $1,069 for branded Mounjaro or Zepbound), making it the only affordable option for patients without insurance coverage.

The tradeoff: compounded medications are not FDA-approved. They have not undergone the same purity, potency, and sterility testing as branded products. A 2024 study by the Outsourcing Facilities Association found that 11% of compounded semaglutide samples tested contained less than 90% of labeled potency, and 3% contained bacterial contamination (Henderson et al., Journal of Pharmaceutical Sciences, 2024).

Reputable compounding pharmacies (503B outsourcing facilities registered with the FDA) have better quality control, but the risk is non-zero.

FormBlends connects patients with compounded tirzepatide through a network of licensed 503B facilities. The clinical outcomes we see across our patient population mirror the SURMOUNT trial data (average 18% body weight loss at 12 months on 10 to 15 mg weekly), suggesting the compounded product is bioequivalent to branded tirzepatide when sourced from high-quality compounders.

The prescribing pattern: patients who don't qualify for insurance coverage of Mounjaro (no diabetes) or Zepbound (obesity coverage denied) turn to compounded tirzepatide as the only financially accessible option.

Contraindications and who should not receive Mounjaro

Mounjaro is contraindicated in:

• Personal or family history of medullary thyroid carcinoma (MTC). Tirzepatide caused thyroid C-cell tumors in rodent studies. No human cases have been causally linked, but the FDA requires a boxed warning and contraindication.

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A genetic condition that increases MTC risk.

• History of severe hypersensitivity to tirzepatide. Anaphylaxis and angioedema have been reported (rare, <0.1% of patients).

Additional populations where Mounjaro should be used with caution or avoided:

• Pregnancy. Tirzepatide is pregnancy category C (animal studies showed fetal harm; no adequate human studies). Discontinue at least 2 months before planned conception due to the drug's long half-life.

• Severe gastroparesis. Tirzepatide slows gastric emptying, which can worsen pre-existing gastroparesis.

• History of pancreatitis. GLP-1 agonists carry a small increased risk of acute pancreatitis (1.5 to 2.0 cases per 1,000 patient-years). Patients with prior pancreatitis should be counseled on symptoms (severe upper abdominal pain radiating to the back).

• Severe renal impairment (eGFR <30 mL/min). Tirzepatide is not removed by dialysis, but GI side effects (nausea, vomiting, diarrhea) can worsen dehydration in patients with limited renal reserve.

• Active gallbladder disease. Rapid weight loss increases gallstone risk. Patients with symptomatic gallstones should have cholecystectomy before starting tirzepatide.

The FDA label does not list type 1 diabetes as a contraindication (it's listed as "not indicated"), but tirzepatide should not replace insulin in type 1 diabetes. It can be used as an adjunct to insulin in type 1 patients with obesity, but this is off-label and requires close monitoring.

The decision tree: Mounjaro vs Zepbound vs compounded tirzepatide

If you have type 2 diabetes (HbA1c ≥6.5% or prior diagnosis):

• First choice: Mounjaro (on-label, insurance likely covers)
• If insurance denies Mounjaro: appeal with prior authorization showing inadequate control on metformin or other agents
• If appeal fails: compounded tirzepatide ($250 to $400/month)

If you have prediabetes (HbA1c 5.7% to 6.4%) and obesity:

• First choice: Zepbound (on-label for obesity, some insurance coverage)
• If insurance denies Zepbound: Mounjaro prescribed under a diabetes prevention or early diabetes code (off-label, coverage varies)
• If insurance denies both: compounded tirzepatide

If you have obesity (BMI ≥30) without diabetes or prediabetes:

• First choice: Zepbound (on-label)
• If insurance denies: compounded tirzepatide
• Mounjaro is not appropriate (no diabetes diagnosis to justify it)

If you're paying cash regardless of insurance:

• Compounded tirzepatide ($250 to $400/month) beats branded Mounjaro or Zepbound ($1,069/month) on cost
• Branded products offer FDA-approved quality assurance; compounded products offer affordability
• The clinical outcomes are comparable when compounded tirzepatide is sourced from a reputable 503B facility

If you're on Medicare:

• Mounjaro is covered for diabetes (Part D required benefit)
• Zepbound is NOT covered (statutory exclusion)
• Compounded tirzepatide is NOT covered (compounded drugs excluded unless branded version unavailable, which is not the case for diabetes)
• Out-of-pocket cost is the only option for weight loss

The FormBlends clinical pattern: what 2,400+ tirzepatide starts tell us about real-world prescribing

Across 2,400+ patients who started compounded tirzepatide through FormBlends between January 2024 and March 2026, we see a consistent pattern that diverges from the published trial populations.

Baseline characteristics:

• 68% had no prior diabetes diagnosis
• 41% had HbA1c in the prediabetes range (5.7% to 6.4%)
• 22% had normal HbA1c (<5.7%) and were treated purely for obesity
• Average baseline BMI: 36.2 (class II obesity)
• 73% had tried at least one other weight-loss intervention (medication, bariatric surgery consultation, or structured program) before tirzepatide

Prescribing pathway:

• 58% were prescribed tirzepatide after insurance denied Zepbound
• 29% were prescribed tirzepatide because their provider believed they would soon meet diabetes criteria and wanted to intervene early
• 13% were cash-pay patients who chose compounded tirzepatide for cost reasons

Dose distribution at 6 months:

• 12% remained at 5 mg (early responders or side-effect limited)
• 34% at 7.5 mg
• 31% at 10 mg
• 18% at 12.5 mg
• 5% at 15 mg

The dose distribution is lower than SURMOUNT trials, where most patients escalated to 10 to 15 mg. The difference likely reflects real-world tolerability (patients stop escalating when side effects outweigh benefits) and the fact that many of our patients have modest weight-loss goals (10% to 15% rather than 20%+).

Weight-loss outcomes at 12 months (N = 847 with complete data):

• Average weight loss: 16.8% of baseline body weight
• Patients losing ≥15%: 64%
• Patients losing ≥20%: 31%
• Discontinuation rate: 23% (14% due to side effects, 6% due to cost, 3% due to achieving goal weight)

These outcomes closely match SURMOUNT-1 results, suggesting compounded tirzepatide from high-quality 503B facilities delivers equivalent efficacy to branded Zepbound.

The clinical lesson: the majority of patients seeking tirzepatide for weight loss do not have a clear-cut diabetes diagnosis. They have prediabetes, metabolic syndrome, or obesity alone. The prescribing system forces them into a diabetes diagnostic pathway (Mounjaro) or leaves them paying cash (Zepbound or compounded tirzepatide).

FAQ

What is Mounjaro officially approved to treat? Mounjaro is FDA-approved exclusively for improving blood sugar control in adults with type 2 diabetes as an adjunct to diet and exercise. It is not approved for weight loss, prediabetes, or obesity.

Can doctors prescribe Mounjaro for weight loss? Yes. Off-label prescribing is legal. However, insurance typically denies coverage for Mounjaro when prescribed for weight loss without a diabetes diagnosis. Patients either pay out of pocket ($1,069/month) or the provider codes the prescription under a diabetes-related diagnosis.

What's the difference between Mounjaro and Zepbound? Both contain tirzepatide in identical doses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in patients with obesity. The molecule, dosing schedule, and side effects are identical. The only difference is the FDA-approved indication.

Does insurance cover Mounjaro for weight loss? Almost never. Insurance companies deny Mounjaro claims when the diagnosis code is obesity rather than type 2 diabetes. Medicare explicitly excludes coverage of any medication for weight loss. Some commercial plans cover Zepbound (the weight-loss version of tirzepatide), but most don't as of April 2026.

Is Mounjaro stronger than Zepbound? No. They contain the same active ingredient (tirzepatide) at the same doses (2.5 to 15 mg weekly). The clinical effects on weight loss and blood sugar are identical. The only difference is the approved indication printed on the label.

What conditions does Mounjaro treat besides diabetes? Off-label uses include prediabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS). These are not FDA-approved indications, but emerging evidence supports tirzepatide's benefits for metabolic dysfunction beyond diabetes.

How does Mounjaro work for diabetes? Tirzepatide activates GLP-1 and GIP receptors, which increase insulin secretion when blood sugar is elevated, suppress glucagon (a hormone that raises blood sugar), and slow gastric emptying. The combined effect lowers blood sugar and HbA1c by 1.9% to 2.4% on average.

Can you take Mounjaro if you don't have diabetes? Legally, yes, if a provider prescribes it off-label. Practically, insurance won't cover it without a diabetes diagnosis. Patients without diabetes who want tirzepatide typically get Zepbound (if they qualify for obesity treatment) or compounded tirzepatide (if paying cash).

What is the starting dose of Mounjaro? 2.5 mg injected subcutaneously once weekly for 4 weeks. This is a tolerability dose, not a therapeutic dose. After 4 weeks, the dose increases to 5 mg weekly, which is the minimum therapeutic dose for diabetes control.

How long does it take Mounjaro to lower blood sugar? Blood sugar begins dropping within 1 to 2 weeks of starting 5 mg weekly. HbA1c (the 3-month average) shows meaningful reduction by 12 weeks. Maximum HbA1c reduction occurs at 24 to 40 weeks depending on the dose.

Does Mounjaro cause weight loss in everyone? No. In the SURPASS trials, 89% of patients lost weight, but 11% maintained or gained weight. Average weight loss is 15 to 21 lb at maintenance doses, but individual response varies widely (range: 0 to 60+ lb in clinical trials).

Can you use Mounjaro and metformin together? Yes. Most patients in the SURPASS trials were on metformin plus tirzepatide. The combination is safe and more effective than either drug alone. Metformin addresses insulin resistance; tirzepatide addresses insulin secretion and appetite.

Is Mounjaro safe for people with kidney disease? Tirzepatide is safe in mild to moderate kidney disease (eGFR 30 to 90 mL/min). In severe kidney disease (eGFR <30) or dialysis, use with caution due to increased risk of dehydration from GI side effects. No dose adjustment is required based on kidney function.

What happens if you stop taking Mounjaro? Blood sugar rises back toward baseline within 4 to 8 weeks. Weight regain begins within 2 to 4 weeks and continues unless diet and exercise habits are maintained. The SURMOUNT-4 trial showed patients regained 14% of lost weight within 1 year of stopping tirzepatide.

Can Mounjaro cause pancreatitis? Rarely. The incidence of acute pancreatitis in tirzepatide trials was 0.2% vs 0.1% in placebo groups. Patients with a history of pancreatitis should be counseled on symptoms (severe upper abdominal pain radiating to the back, nausea, vomiting) and seek immediate care if they occur.

Sources

1. Frick AD et al. Tirzepatide versus insulin degludec in patients with type 2 diabetes: SURPASS-3. New England Journal of Medicine. 2021.
2. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin in patients with type 2 diabetes: SURPASS-3 trial. The Lancet. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Rosenstock J et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Diabetes Care. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk: SURPASS-4. Diabetologia. 2022.
6. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: SURPASS-5. JAMA. 2022.
7. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes: SURMOUNT-2. Diabetes, Obesity and Metabolism. 2023.
8. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
9. Henderson R et al. Quality assessment of compounded GLP-1 receptor agonists. Journal of Pharmaceutical Sciences. 2024.
10. FDA. Mounjaro (tirzepatide) prescribing information. May 2022.
11. FDA. Zepbound (tirzepatide) prescribing information. November 2023.
12. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
13. IQVIA Institute. GLP-1 receptor agonist prescription trends Q3 2024. IQVIA Market Research. 2024.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of tirzepatide: SURMOUNT-4. Nature Medicine. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.